Logo

Invivyd, Inc.

IVVD

Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Thera… read more

Healthcare

Biotechnology

4 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$0.55

Price

+3.10%

$0.01

Market Cap

$162.505m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-297.5%

EBITDA Margin

-301.2%

Net Profit Margin

-308.8%

Free Cash Flow Margin

-297.5%

EBITDA Margin

-301.2%

Net Profit Margin

-308.8%

Free Cash Flow Margin
Revenue

$55.866m

+4.6%

1y CAGR

+38.4%

3y CAGR

+28.8%

5y CAGR
Earnings

-$77.600m

-47.8%

1y CAGR

+11.9%

3y CAGR

+13.4%

5y CAGR
EPS

-$0.37

-23.3%

1y CAGR

+25.6%

3y CAGR

+23.3%

5y CAGR
Book Value

$203.050m

$241.742m

Assets

$38.692m

Liabilities

$8.626m

Debt
Debt to Assets

3.6%

-0.1x

Debt to EBITDA
Free Cash Flow

-$79.455m

-36.3%

1y CAGR

+10.5%

3y CAGR

+13.2%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases